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Abstract: A simple and rapid method has been developed for
testing bacterial endotoxin in hyaluronic acid (HA)-based medi-
cal devices. High-molecular-weight HA (HMW HA) in solution
or HA-based medical devices was digested by the enzyme hya-
luronidase to reduce solution viscosity by truncating the long
chains of HA and to test for bacterial endotoxin. The bacterial
endotoxin level was detected and measured by kinetic chromo-
genic Limulus Amebocyte Lysate (LAL) assay. The method was
applied to two different ophthalmic viscosurgical devices
(OVDs) and one dermal filler, and may easily be adapted to use
with up to 3% HA solutions and other HA-based medical
devices. Published 2016. This article is a U.S. Government work and is
in the public domain in the USA. J Biomed Mater Res Part B: Appl Bio-
mater, 105B: 1210–1215, 2017.
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INTRODUCTION
Hyaluronic acid (HA) has unique biochemical and physical
properties that make it an important biomaterial for several
medical device applications. These include its use as oph-
thalmic viscoelastic device (OVD) during cataract surgery,1
injections to treat joints with osteoarthritis2, cosmetic der-
mal fillers3; and also its use as antiadhesion barriers in sur-
geries.4 However, once implanted, HA undergoes
biodegradation which is frequently accompanied by inflam-
mation of tissue. HA is often derived from animal tissue and
bacteria, and may be contaminated with bacterial endo-
toxin.5 Bacterial endotoxin (lipopolysaccharides (LPS) from
outer membrane of Gram-negative bacteria) can cause pain-
ful inflammation, leading to failure of the device. The U.S.
Food and Drug Administration (FDA) recommends a maxi-
mum allowed limit of endotoxin that may be present in
medical devices which are in contact with blood, cerebrospi-
nal fluid, or implanted in the body5; or single-use intraocu-
lar ophthalmic devices.6 Bacterial endotoxin contamination
may be introduced at any stage of the HA-based medical
device manufacturing process. There are several potential
sources of the endotoxin contamination: water, chemicals,
and raw materials involved in manufacturing, packaging
components, equipment, and factory employees. The quality
and purity of all materials involved in manufacturing have
to be established and controlled at every stage of the pro-
cess. A final medical device product, that is intended for
implantation in general or intended to come in contact with
blood or cerebrospinal fluid, or ocular tissues, has to meet
its endotoxin limit by being tested for bacterial endotoxin.5,6
Several reports suggested that HA-based products may
have been contaminated with bacterial endotoxin5; and in
effect, may have caused inflammatory reactions in patients
who received short- or long-term implantation.2,7,8 OVDs
fabricated from HMW HA are indicated for use during cata-
ract surgery.9 Toxic anterior segment syndrome (TASS) is a
noninfectious eye inflammation that can occur after cataract
surgery, leading to glaucoma and damaging the cornea and
retina.10 It has been demonstrated that OVDs composed of
high molecular weight HA, and contaminated with bacterial
endotoxin, may cause TASS.11 A number of TASS outbreaks
over the past 11 years have affected patients from many
surgical centers in North America.12 FDA researchers inves-
tigated the causes of TASS outbreaks as adverse events13;
and developed new testing methods to determine the
inflammatory potential of suspected contamination of sub-
ject devices.14–21
In 2012, Buchen et al. evaluated an inflammatory poten-
tial of cohesive and dispersive OVDs which were spiked
with known endotoxin concentrations,13 and were measured
using the LAL kinetic turbidimetric assay. Rabbits were
given known concentrations of bacterial endotoxins mixed
with HA and the researchers noted the concentration at
which of endotoxin caused inflammation in the eye. They
also noted that because the HA was so viscous, it was diffi-
cult to obtain accurate amount of samples to measure
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bacterial endotoxins using the LAL assay.13 Dermal fillers
require minimal surgical intercession because they can be
easily delivered under the skin via injection. This fact led to
the development and approval of several HA-based dermal
fillers since the first one cleared by FDA in 2003. According
to FDA’s Medical Device Reports (MDR), however, there
were 930 adverse events associated with use of the dermal
fillers between 2003 and September 20, 2008.16 These
events may have occurred due to the surgical procedure
technique (depth and the correct placement of injection
itself), concentration of the product used (excessive
amount), protein and endotoxin contamination, and low-
molecular-weight HA fragments generated during biological
degradation.8,17–20
The focus of this study is to develop a simple and rapid
method for testing the presence of bacterial endotoxin in
HA-based medical devices. High-molecular-weight HA sam-
ples were first digested using hyaluronidase enzyme and
then, the Limulus ameboycte lysate (LAL) chromogenic
kinetic test method was used to detect and quantify the
amount of bacterial endotoxin in the HA digests. Out of
three different commercially available sources of hyaluroni-
dases, we found two were contaminated with bacterial
endotoxin. We therefore used the clinically available hyalu-
ronidase (i.e., recombinant hyaluronidase), which had no
endotoxin contamination, to digest three different HA-based
medical devices.
We found that hyaluronidase digestion of high viscosity
HA prior to endotoxin measurements can greatly aid the
detection of bacterial endotoxins in implantable HA-based
medical devices.
MATERIALS AND METHODS
Hyaluronic acid
Dry HA powder samples with the average molecular weights
of 1.2–1.8 MDa and low endotoxin content (specification at
less than 0.07 EU/mg) were purchased from LifeCore Bio-
medical, LLC (Chaska, MN, USA). The research grade sodium
hyaluronate was derived from pharmaceutical grade batches
and met the Lifecore Biomedical’s sodium hyaluronate phar-
maceutical specifications. The HA samples were solubilized
in sterile endotoxin-free water (Lonza) at 2.0 and also, at
20.0 mg/mL.
HA-based medical devices
Samples of commercially available OVDs, containing 1% and
3% HA were tested. Upon the manufacturer’s recommenda-
tions, they were stored at 28–88C before use. The dermal fil-
ler was a gel of HA produced by Streptococcus species,
chemically cross-linked with BDDE (1, 4-butane-diol digly-
cidyl ether), stabilized and suspended in phosphate buffered
saline at pH5 7 and at HA concentration of 20 mg/mL. The
dermal filler was stored at up to 258C with no exposure to
direct sunlight upon the manufacturer’s recommendations.
Hyaluronidase
Hyaluronidases from bovine testes and from Streptomyces
hyalurolyticus were purchased from Sigma–Aldrich Chemical
Co. (St Louis, MO, USA). Following the manufacturer’s
instructions, the testicular enzyme was dissolved in cold
20 mM sodium phosphate buffer and used at 1,450 U/mL.
Also following the same, the Streptomyces was dissolved in
pH 7.0 with 77 mM sodium chloride or in endotoxin-free
water, and used at 200 U/mL. The recombinant hyaluronidase
solution (150 USP units/mL) was purchased from Halozyme
Therapeutics, Inc. (San Diego, CA, USA) and following the
manufacturer’s recommendations, it was stored in a refrigera-
tor at 28–88C. Each milliliter of the recombinant hyaluronidase
solution contained 150 USP units of recombinant human hya-
luronidase with 8.5 mg sodium chloride, 1.4 mg dibasic
sodium phosphate, 1 mg albumin human, 0.9 mg EDTA,
0.3 mg calcium chloride, and sodium hydroxide added for pH
adjustment. The enzyme solution pH was 7.0.
Lipopolysaccharide (endotoxin)
LPS from Escherichia coli serotype O26:B6 (endotoxin), pur-
chased from Sigma Aldrich, was reconstituted with dimethyl
sulfoxide (DMSO, Sigma) to a concentration of 250 mg/mL
and frozen in aliquots at 2708C until use.
Enzymatic digestion
The HA samples and HA-based medical devices were
digested by adding 40 units of recombinant hyaluronidase
to 1 mL of HA sample and mixing for 10 s at high speed
with a vortex mixer. All digestion experiments were per-
formed at room temperature, and the samples were shaken
on a 55D Double Platform Shaker for 24 h at 55 rpm at
room temperature. Sample degradation was confirmed by
observing changes of viscosity of the samples. The digested
HA samples were stored in a freezer at 2208C prior to LAL
assay.
Endotoxin detection
Endotoxin was assayed according to the instructions with
the Lonza Kinetic-QCL Chromogenic Limulus Amoebocyte
Lysate (LAL) Endotoxin Assay kit with a sensitivity range of
0.005–50.0 EU/mL (Walkersville, MD). Both positive and
negative controls were included with each assay. A set of
standards of known concentrations of bacterial endotoxins
was included on each assay run. The correlation coefficients,
or R2 values, for the standard curves were between 0.9855
and 0.9957.
Viscosity measurements
Using a rotational rheometer (AR-G2, TA instruments, Dela-
ware, USA) with a 60-mm-diameter stainless-steel cone-and-
plate geometry (truncation angle 28), viscosity was meas-
ured at 0.1/s shear rate for 30 min at room temperature
before enzyme addition. Enzyme was added to HA on the
rheometer plate and the viscosity was measured again, at
the same rate for 30 min immediately after enzyme addition
and from 1.25 to 1.75 h after enzyme addition. Using the
same experimental conditions, shear viscosities of HA chains
were also measured between 0.01/s and 10/s shear rates,
followed by an immediate reverse cycle from 10/s to 0.01/s
shear rates. High-concentration (3%) HA sample from OVD
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was used to confirm reduction in viscosity by enzymatic
degradation; and rooster comb HA from Sigma–Aldrich was
prepared at 3% concentration and tested using the same
protocol for comparing changes in viscosity.
RESULTS
In this study, we developed a simple and rapid method for
testing for the presence of bacterial endotoxin in high-
molecular-weight HA-based medical devices. Enzymatic
digestion of HA prior to endotoxin measurements is a
method which exposes the HA bacterial endotoxin, thereby
allowing it to be measured easily using the LAL assay.
Hyaluronidases testing for the bacterial endotoxin
Figure 1 represents that the bacterial endotoxins in hyaluro-
nidases from bovine testes (BT HAase) were at 13.18 EU/
mL and that in Streptomyces hyalurolyticus (Sh HAase) were
at 14.7 EU/mL. Both the recombinant human hyaluronidase
and the endotoxin-free water tested negative for the pres-
ence of endotoxin. The recombinant human HAase was cho-
sen for enzymatic degradation of all our HA test samples.
Bacterial endotoxin detection in HA solutions and
HA-based medical devices
Figure 2 shows the results of the bacterial endotoxin
detected in enzyme-digested HA samples. The manufacturer
FIGURE 1. Average of endotoxin levels in three different sources hyaluronidases: recombinant (Hylenex HAase), Bovine testes (BT HAase), Strep-
tomyces hyalurolyticus (Sh HAase), and in the positive and negative controls (PC and NC), respectively. The endotoxin activity of the hyaluroni-
dases was determined by kinetic chromogenic LAL assay. Values in bar graphs shown represent the means of three experiments6 standard
deviation (SD) of 3 replicate wells per sample.
FIGURE 2. Endotoxin detection in hyaluronic acid of two concentrations, 0.2% and 2.0% before and after degradation for 24 h and hyaluronidase at
150 U/mL (enzyme), and in the positive and negative controls (PC and NC), respectively. The endotoxin activity of the samples was determined by
kinetic-chromogenic LAL assay. Values in bar graphs shown represent the means of three experiments6SD of 3 replicate wells per sample.
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of these samples claimed <0.07 EU/mg of endotoxin when
diluted in sterile endotoxin-free water with low endotoxin
content. The HA samples were used at two different concen-
trations, 0.2% and 2.0%; and after an enzymatic digestion,
neither of the HA samples showed any detectable level of the
bacterial endotoxin when tested for and compared to the neg-
ative control (NC, endotoxin-free water) and positive control
(PC, E. coli 055:B5 Endotoxin standard at 0.5 EU/mL).
Figure 3 represents the bacterial endotoxin detection in
enzyme-digested original solutions (1.0% and 3.0%) of OVDs
compared to two of the assay controls: negative, NP (endo-
toxin-free water) and positive, PC (LAL assay standard at 50
EU/mL). Three independent experiments were performed
with each sample and three replicas per test condition.
Results suggest that the 3% HA OVD was contaminated with
the bacterial endotoxin from the outset, whereas the 1% HA
OVD showed no detectable level of the bacterial endotoxin.
Nondigested 3% HA OVD alone cannot be assayed for the
presence of bacterial endotoxin because of its high viscosity13
and difficulty in handling small volumes accurately.
Figure 4 shows the results of bacterial endotoxin detec-
tion in 2% HA-based dermal filler, as received or spiked
with 24 EU/mL of bacterial endotoxin, which were then
digested prior to testing. Two independent experiments
were performed with each set of samples with either four
or six replicas per test condition. The results for nondi-
gested and digested dermal fillers, which were not spiked
with LPS, showed absence of significant amounts of endo-
toxin when assayed. However, the digested endotoxin-spiked
dermal filler revealed higher bacterial endotoxin level than
the nondigested sample.
Viscosity
Figure 5 confirms the change in viscosity of 3% OVD sample
after enzymatic degradation, and compares it with the same
for 3% rooster comb HA samples. At a constant shear rate
of 0.1/s, the viscosity of both samples are constants and
comparable for the first half hour. The viscosity of HA from
rooster comb (RC) declined at much faster rate than that
from OVD, immediately within the first half hour after the
enzyme addition. When measured again between 1.25 and
1.75 h after enzyme addition, the viscosities values of both
samples reduced considerably from their initial values. In
addition, shear viscosities of each sample, which were com-
parable for both the forward (
$
) and the reverse (
Q
) curves,
changed considerably immediately after enzyme addition
(middle and right panel in Figure 5). Noticeably, the viscos-
ity on RC samples declined to 2 Pa s within the first hour,
while that of the OVD sample changed to 4–5 Pa s after 8 h.
However, it is a 10-fold decrease from its original value and
in the actual experiment, the samples were treated for 24 h
with enzyme, and before running LAL assay.
DISCUSSION
Reagents or chemicals that are used in research and in man-
ufacturing of medical devices can be contaminated. Possible
sources of contamination include water, raw materials that
contain lipopeptides, peptidoglycans, endotoxin, or other
proteins.14,22 Bacterial endotoxin is known to bind to other
chemicals as well as to many surfaces,23 revealing lower
than tangible levels in the actual device. For example, the
LAL assay could be exaggerated (3% HA of OVD) or under-
estimated (endotoxin-spiked dermal filler), especially in
high-viscosity HA solutions or gels.
Our results suggest that in HA, bacterial endotoxin
detected by LAL kinetic assay was at least 2 times lower
than in an endotoxin solution at 24 EU/mL alone. Since the
molecular weight of a polymer chain is proportional to its
viscosity, and OVDs (containing 3% HA) and dermal fillers
FIGURE 3. The average of endotoxin levels in 1% HA OVD and 3% HA OVD (HA-based ophthalmic viscosurgical devices at 1.0% and 3% of HA,
respectively) before and after digestion for 24 h and hyaluronidase at 150 U/mL (enzyme). The endotoxin activity of the samples was determined
by kinetic chromogenic LAL assay. Values in bar graphs shown represent the means of three experiments6SD of 3 replicate wells per sample.
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(containing 2% HA) are high viscosity solutions (Figure 5),
they contain long-chain HA molecules.
Figure 5 shows that under a steady flow, comparable
concentrations of HA from two different sources (OVD and
rooster comb) have high viscosities toward the “zero shear”
limit, but fairly low viscosity at higher shear rates which
recovered to the original viscosity value during reverse
tracking (Figure 5, middle and right panels). This recovery
suggested the presence of entangled HA chains which
opened up under high shear; otherwise if the decrease in
viscosity at a high shear was due to chain scission, it would
not have recovered close to the original value. Viscosity
FIGURE 5. Comparison of viscosities of 3% ophthalmic HA (OVD) sample (•, , 1) and 3% rooster comb HA (RC) (, w, x) samples; and shows
that the viscosity values for both the original samples are in close range, the rate of change in viscosities after enzyme addition varied tremen-
dously; however, the trends are similar. Left panel represents the respective viscosities of OVD and RC samples at a constant 0.1/s shear rate
over time prior to enzyme addition (•, ) and up to half after (, w) after enzyme addition, and also, within 1.25–1.75 h (1, x) since enzyme
addition. Middle panel represents the shear viscosities of the OVD samples with increasing shear rate (•) followed by an immediate decreasing
shear rate (1) before enzyme addition, and the same (,2 respectively) immediately after enzyme addition. Right panel represents the shear vis-
cosities of RC samples with increasing () and immediately decreasing shear rate (x) before enzyme addition, and the respective (w, D) immedi-
ately after enzyme addition.
FIGURE 4. Average of endotoxin levels in HA-based dermal filler (DF) and HA-based dermal filler spiked with endotoxin at 24 EU/mL (DF1LPS)
before and after digestion for 24 h and in hyaluronidase at 150 U/mL (Enzyme), and endotoxin at 24 EU/mL (LPS). The endotoxin activity of the
samples was determined by kinetic chromogenic LAL assay. Values in bar graphs shown represent the means of two experiments6SD of 4 rep-
licate wells per sample.
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measurements confirmed that enzyme application reduced
the viscosity of the highest concentration HA solution signif-
icantly, which is a signature of reduction in molecular
weight and therefore a reduction in entanglement. Such
entanglements in the original HA-solutions may have con-
cealed some of the bacterial endotoxin within the chain
folds. Therefore, it may be necessary to use endotoxin-free
hyaluronidase to break down the large HA molecule and
make endotoxin more accessible for LAL testing, which is
otherwise performed under immobile conditions, that is, in
the presence of entanglements. In this study, a simple
method was developed to show that digestion of HA by hya-
lurondase prior to LAL assay can be used to accurately
account for bacterial endotoxin in highly viscous HA solu-
tions can be obtained after its digestion. This HAase treated
HA method may allow detection of the presence of bacterial
endotoxin without the use of animals.20 The results of this
study may help to increase the accuracy of endotoxin meas-
urements by LAL assay, to ensure safety of the HA-based
medical devices and help to evaluate for this potential cause
of inflammation by these devices. Detection of bacterial
endotoxin during the manufacturing processes can be moni-
tored to allow the manufacturers to detect and measure the
presence of bacterial endotoxin in their final products.
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